Literature DB >> 7512071

Immunocytochemical characterization of cell lines from human malignant mesothelioma: characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies.

L Zeng1, J Fleury-Feith, I Monnet, C Boutin, J Bignon, M C Jaurand.   

Abstract

A panel of nine monoclonal antibodies was used to characterize human mesothelioma cell lines that we established from human malignant mesothelioma. The antigens detected were cytokeratin, vimentin, epithelial membrane antigen, carcinoembryonic antigen, Leu-M1 (CD15), desmin, factor VIII-related antigen (von Willebrand factor antigen), OV632, and ME1, a specific monoclonal antibody directed against human malignant mesothelioma. The technique used was the alkaline phosphatase anti-alkaline phosphatase method. All 30 cell lines, either epithelial, sarcomatous, or mixed, showed strong reactivity with cytokeratin and vimentin antibodies. None of the cell lines demonstrated any reactivity with carcinoembryonic antigen, Leu-M1, or factor VIII antibodies; moreover, all of 22 cell lines studied were positive for ME1 antibody and 10 of 12 cell lines studied were positive for OV632. Some interesting features were noted: only two of the 30 cell lines presented a weak positive staining with epithelial membrane antigen, and nine of 19 cell lines tested demonstrated a cytoplasmic staining pattern with desmin antibody. These results show that established human mesothelioma cell lines still possess the immunocytochemical characteristics that are basically consistent with the immunohistochemical features described in tumor tissues of malignant mesothelioma. These characteristics can be used to identify the mesothelioma cells grown from human malignant mesothelioma. Hence, the mesothelioma cell lines will provide a useful tool for the investigation of the cell biology of the tumor and the mechanisms of mesothelial cell transformation, as well as the in vitro evaluation of the effects of some drugs in order to develop new therapies for malignant mesothelioma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512071     DOI: 10.1016/0046-8177(94)90192-9

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

1.  Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis.

Authors:  Marie-Marthe Philippeaux; Jean-Claude Pache; Sophie Dahoun; Marc Barnet; John-Henri Robert; Jacques Mauël; Anastase Spiliopoulos
Journal:  Histochem Cell Biol       Date:  2004-09-15       Impact factor: 4.304

2.  Novel human single chain antibody fragments that are rapidly internalizing effectively target epithelioid and sarcomatoid mesotheliomas.

Authors:  Arun K Iyer; Xiaoli Lan; Xiaodong Zhu; Yang Su; Jinjin Feng; Xiaoju Zhang; Dongwei Gao; Youngho Seo; Henry F Vanbrocklin; V Courtney Broaddus; Bin Liu; Jiang He
Journal:  Cancer Res       Date:  2011-03-29       Impact factor: 12.701

3.  Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology.

Authors:  P Harvey; A Warn; S Dobbin; N Arakaki; Y Daikuhara; M C Jaurand; R M Warn
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

4.  In vitro and in vivo characterization of highly purified human mesothelioma derived cells.

Authors:  Alice Melotti; Antonio Daga; Daniela Marubbi; Annalisa Zunino; Luciano Mutti; Giorgio Corte
Journal:  BMC Cancer       Date:  2010-02-22       Impact factor: 4.430

5.  Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma.

Authors:  Scott Bidlingmaier; Jiang He; Yong Wang; Feng An; Jinjin Feng; Dario Barbone; Dongwei Gao; Ben Franc; V Courtney Broaddus; Bin Liu
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

6.  Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages.

Authors:  Derya Gümürdülü; E Handan Zeren; Philip T Cagle; Fazilet Kayasel uk; Nazan Alparslan; Ali Kocabas; Ilhan Tuncer
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

7.  Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies.

Authors:  Feng An; Daryl C Drummond; Shannon Wilson; Dmitri B Kirpotin; Stephen L Nishimura; V Courtney Broaddus; Bin Liu
Journal:  Mol Cancer Ther       Date:  2008-03-04       Impact factor: 6.261

8.  Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood.

Authors:  N P Wang; J Marx; M A McNutt; J C Rutledge; A M Gown
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

9.  Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases.

Authors:  P Harvey; I M Clark; M C Jaurand; R M Warn; D R Edwards
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

10.  Cell cycle checkpoint status in human malignant mesothelioma cell lines: response to gamma radiation.

Authors:  C Vivo; C Lecomte; F Levy; K Leroy; Y Kirova; A Renier; L Kheuang; P Piedbois; D Chopin; M C Jaurand
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.